

#8

Attorney Ref: 331D USD1

JC978 U.S. PTO  
09/834424  
04/13/01

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Applicants</b>	:	Schreiber and Crabtree
<b>Serial No.</b>	:	Not yet assigned
<b>Filed.</b>	:	Herewith
<b>Examiner</b>	:	
<b>Group Art Unit</b>	:	
<b>For</b>	:	<i>Methods and Materials Involving Dimerization-Mediated Regulation of Biological Events</i>

Assistant Commissioner for Patents  
Washington, DC 20231

April 13, 2001

**Information Disclosure Statement Under 37 CFR §1.97(B)**

Applicants and their agents/attorneys are aware of the following publications and information, and in accordance with 37 C.F.R. § 1.97 and § 1.98, wish to make them of record. Form PTO-1449 is enclosed.

The Examiner is respectfully requested to initial the space adjacent to each documents on the PTO-1449 form and return a copy of the PTO-1449 form to confirm that these documents have been considered by the Examiner and made of record in this application.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited publications.

No additional costs are believed to be due in connection with the filing of this disclosure. However, please charge any necessary fees to our Deposit Account No. 01-2315.

Should there be any questions after review of this paper, the Examiner is invited to contact the undersigned at (617) 494-0400 x266.

Respectfully submitted,



David L. Bernstein, Reg. No. 31,235  
ARIAD Pharmaceuticals, Inc.  
26 Landsdowne Street  
Cambridge, MA 02139  
Telephone: 617-494-0400 Ext. 266  
Facsimile: 617-494-0208